Weight loss is linked to decreased risk of colon and rectal polyps

Share This Post

May 2022: According to study findings published February 1 in the Journal of the National Cancer Institute, overweight or obese adults who lose more than 5 pounds over five years have a 46 percent lower risk of developing precancerous colon polyps, which are benign growths in the colon or rectum that can lead to colorectal cancer.


Body weight and colon cancer


From 1993 to 2001, researchers looked examined the relationship between weight change and colon and rectal polyps in 18,588 men and women who took part in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening study. People who have self-reported their weight three times during the course of their life were included in the study. The case group included 1,053 persons who acquired polyps three to five years into the study, while the control group included those who did not. Those who dropped weight throughout early to late adulthood had a much lower risk of having polyps than those who maintained their weight, especially if they were initially overweight (had a BMI of more than 25). People who gained weight during the trial, on the other hand, had a 1.3 times higher risk of getting polyps. In comparison to women, the link appeared to be stronger in men.

Researchers have discovered for the first time that limiting weight gain during adulthood lowers the risk of acquiring precancerous growths that can lead to colorectal cancer. The advantages appear to be linked to being overweight or obese.


Spread the love

Subscribe To Our Newsletter

Get updates and never miss a blog from Cancerfax

More To Explore

Development of CAR T Cell therapy in Korea
Cancer treatment in South Korea

Companies in Korea takes a step closer in developing home grown CAR T-Cell therapy

Due to high costs, treatments developed by multinational pharmaceutical corporations are difficult for Korean patients to access. As a result, Korean businesses have created and localised CAR-T treatments in an effort to address these issues. Many businesses have either begun developing CAR-T therapies or declared their intention to do so, including Curocell, Abclon, GC Cell, Ticaros, Helixmith, Toolgen, Cllengene, Eutilex, and Vaxcell Bio.

Spread the love
Blood cancer

Polatuzumab vedotin-piiq is approved by USFDA for previously untreated diffuse large B-cell lymphoma, not otherwise specified, and high-grade B-cell lymphoma

For adult patients with high-grade B-cell lymphoma (HGBL), not otherwise specified (NOS), or diffuse large B-cell lymphoma (DLBCL) who have not previously received treatment and who have an International Prognostic Index (IPI) score of 2 or higher, the Food and Drug Administration has approved polatuzumab vedotin-piiq (Polivy, Genentech, Inc.).

Spread the love

Need help? Our team is ready to assist you.

We wish a speedy recovery of your dear and near one.

درمان سرطان در تركيه

Enquiry Form